Purple Biotech (PPBT) Total Current Liabilities (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Total Current Liabilities data on file, last reported at $4.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $4.6 million, up 66.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (up 66.53% YoY), and the FY2025 annual result was $7.8 million, up 94.46% from the prior year.
• Total Current Liabilities fell to $4.6 million in Q1 2026 per PPBT's latest filing, from $7.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $9.7 million in Q4 2023 and troughed at $2.2 million in Q2 2025.
• A 5-year average of $5.9 million and a median of $5.9 million in 2022 frame the typical range for Total Current Liabilities.
• On a YoY basis, Total Current Liabilities climbed as much as 94.46% in 2025 and fell as far as 67.59% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $7.1 million in 2022, then jumped by 37.45% to $9.7 million in 2023, then tumbled by 58.9% to $4.0 million in 2024, then jumped by 94.46% to $7.8 million in 2025, then tumbled by 40.76% to $4.6 million in 2026.
• Business Quant data shows PPBT's Total Current Liabilities at $4.6 million in Q1 2026, $7.8 million in Q4 2025, and $6.1 million in Q3 2025.